Clinical Trial Update: Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating decitabine and vorinostat conditioning followed by CD3-/CD19- NK cell infusion in high-risk myelodysplastic syndrome; study completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Decitabine (Decitabine)
• NK cell infusion
• Vorinostat (vorinostat)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2017-06-14